inclusion criteria: * contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies * all participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration * participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine * must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study * must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (ecoa) (that is, the coronavirus disease-2019 \[covid 19\] signs and symptoms surveillance question, the e-diary, and the electronic patient-reported outcomes (epros). note: participants with visual impairment are eligible for study participation and may have caregiver assistance in completing the electronic clinical outcome assessment (ecoa) questionnaires

inclusion criteria: * contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies * all participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration * participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine * must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study * must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (ecoa) (that is, the coronavirus disease-2019 \[covid 19\] signs and symptoms surveillance question, the e-diary, and the electronic patient-reported outcomes (epros). note: participants with visual impairment are eligible for study participation and may have caregiver assistance in completing the electronic clinical outcome assessment (ecoa) questionnaires

inclusion criteria: contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies all participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (ecoa) (that is, the coronavirus disease-2019 [covid 19] signs and symptoms surveillance question, the e-diary, and the electronic patient-reported outcomes (epros). note: participants with visual impairment are eligible for study participation and may have caregiver assistance in completing the electronic clinical outcome assessment (ecoa) questionnaires

inclusion criteria: contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies all participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (ecoa) (that is, the coronavirus disease-2019 [covid 19] signs and symptoms surveillance question, the e-diary, and the electronic patient-reported outcomes (epros). note: participants with visual impairment are eligible for study participation and may have caregiver assistance in completing the electronic clinical outcome assessment (ecoa) questionnaires

None

None

inclusion criteria: - contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies - all participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration - participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine - must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study - must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (ecoa) (that is, the coronavirus disease-2019 [covid 19] signs and symptoms surveillance question, the e-diary, and the electronic patient-reported outcomes (epros). note: participants with visual impairment are eligible for study participation and may have caregiver assistance in completing the electronic clinical outcome assessment (ecoa) questionnaires

inclusion criteria: - contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies - all participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration - participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine - must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study - must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (ecoa) (that is, the coronavirus disease-2019 [covid 19] signs and symptoms surveillance question, the e-diary, and the electronic patient-reported outcomes (epros). note: participants with visual impairment are eligible for study participation and may have caregiver assistance in completing the electronic clinical outcome assessment (ecoa) questionnaires

inclusion criteria: - contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies - all participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration - participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine - must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study - must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (ecoa) (that is, the coronavirus disease-2019 [covid 19] signs and symptoms surveillance question, the e-diary, and the electronic patient-reported outcomes (epros)

inclusion criteria: - contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies - all participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration - participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine - must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study - must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (ecoa) (that is, the coronavirus disease-2019 [covid 19] signs and symptoms surveillance question, the e-diary, and the electronic patient-reported outcomes (epros)